Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22733317 | 0.89 | KMT2A (0.34) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL14729276 | 0.85 | L3MBTL1 (0.36) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL18145848 | 0.85 | L3MBTL1 (0.36) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL14729303 | 0.83 | KMT2A (0.41) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL18161562 | 0.83 | KMT2A (0.41) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL18145473 | 0.83 | KMT2A (0.41) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL18145426 | 0.78 | L3MBTL1 (0.34) | L3MBTL1KMT2APOLBHDAC8CYP2D6 | |
| SCHEMBL14729299 | 0.78 | L3MBTL1 (0.34) | L3MBTL1KMT2APOLBHDAC8CYP2D6 | |
| SCHEMBL21541230 | 0.77 | FOLH1 (0.38) | L3MBTL1KMT2APOLBHDAC8 | |
| SCHEMBL16094006 | 0.77 | FOLH1 (0.38) | L3MBTL1KMT2APOLBHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032286-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210024574-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200377549-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377549-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | L3MBTL1 4197/4885KMT2A 3251/4885POLB 3330/4885 |
| US-20210032286-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | L3MBTL1 4197/4885KMT2A 3251/4885POLB 3330/4885 |
| US-20210024574-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | L3MBTL1 4197/4885KMT2A 3251/4885POLB 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.